Quantcast

Industry news that matters to you.  Learn more

Parsortix Research Partnership with the Paterson Institute for Cancer Research

Reading time: 3 – 4 minutes

ANGLE plc (AIM: AGL) is pleased to announce that Parsortix Inc (“Parsortix”), its 90% owned portfolio company which specialises in cancer diagnostics, has signed a two year research agreement with the Cancer Research UK-funded Paterson Institute for Cancer Research, The University of Manchester’s world-leading cancer research institute.

ANGLE will be working with the Paterson Institute’s Clinical and Experimental Pharmacology Group (CEP), which specialises in circulating tumour cells (CTCs). The Parsortix CTC research at the Paterson will be led by CEP director Professor Caroline Dive and her deputy Dr Ged Brady.

The Paterson Institute has had acclaim for its work validating biomarkers based on CTCs, which have specific relevance for the treatment of cancer patients. As recently as November 2011, Professor Dive’s Group won the Cancer Research UK Translational Cancer Research Prize for work that included defining the prognostic utility of CTCs in lung cancer patients. Application of CEP’s expertise in bio-markers will be highly beneficial to facilitating the development of Parsortix’s CTC capture device and taking this to market, ultimately to benefit cancer patients.

The main areas of focus for the collaborative work will include:

  1. cancer patient blood studies to provide further independent confirmation of the performance of the Parsortix device and to optimise its design;
  2. development of research and clinical applications of the Parsortix device utilising cancer biomarkers;
  3. evaluation of the Parsortix cassette CTC capture characteristics in relation to other CTC technology platforms;
  4. in-depth comparative studies to support regulatory approval submissions by Parsortix for CE marking in Europe and FDA approval in the United States.

In addition to Parsortix’s focused in-house capability, outsourcing research and development activity provides ANGLE with cost-effective access to world class expertise, capability and facilities and provides the CEP group with new avenues to extend its CTC research.

The Paterson Institute is a key opinion leader in the cancer field and we believe that its active involvement in the development of new applications for Parsortix’s cancer diagnostic device will assist greatly in the marketing of the product first to the research market and then for clinical use to assist treatment decisions in cancer patients.

Professor Caroline Dive, Group Leader, Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, commented:

We are delighted to be working with ANGLE. The Parsortix cell separation technology offers the potential for improved capture of CTCs from cancer patient blood and, since it does not rely on antibody affinity capture, has the potential to be both more effective and more widely applicable than existing techniques. We hope to be able to recover viable CTCs from the Parsortix device and be able to detect useful predictive and/or pharmacodynamic biomarkers, which will enable both an improvement in patient treatment and better targeted, more effective clinical trials of new cancer drugs in the future.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

The Paterson Institute has world-leading knowledge of CTCs and first hand experience of working with existing and developing CTC capture techniques. It is also a leader in research on the bio-markers that can be detected on CTCs. We believe that this research partnership will significantly help us to optimise our cancer diagnostic product and bring it to market as quickly as possible.

Source: ANGLE